Hikma cuts cash consideration for Roxane by £370m
10th Feb 2016 07:15
(ShareCast News) - Hikma Pharmaceutical's takeover of Roxane Laboratories took on a new shape on Wednesday, with the cash consideration being almost halved off the back of significantly lower revenue projections. The FTSE 100 company had published a prospectus on 22 January in relation to the acquis
Read moreFTSE 100 movers: BP leads market fallers on losses
2nd Feb 2016 14:13
(ShareCast News) - The FTSE 100 was back below 6,000 on Tuesday, dropping 151.22 points (2.5%) to 5,908.88 by mid-afternoon. BP took the biggest hit after $2.6bn of write-downs and restructuring charges sent it crashing into losses for the fourth quarter and full year. A $3.31bn loss was reported f
Read moreTuesday newspaper share tips: Hikma Pharmaceuticals and Shire under the microscope
3rd Nov 2015 11:20
(ShareCast News) - Pharmaceuticals were on the newspaper pundits' agenda on Tuesday after Hikma Pharmaceuticals caused a bit of pain. The FTSE 100 company warned on Monday that its generics division is performing below expectations due to slower-than-expected growth in sales for its gout treatment M
Read moreFTSE 100 movers: Travis Perkins builds gains; Hikma slumps on generics business
2nd Nov 2015 14:21
(ShareCast News) - London's FTSE 100 was down 0.1% to 6,355.80 at 1445 GMT, as investors weighed up mixed Chinese manufacturing data against better-than-expected UK factory data, with broker notes providing much of the action. Hikma Pharmaceuticals slumped after lowering its guidance for the generic
Read moreLondon open: Stocks slide on further contraction in China manufacturing
2nd Nov 2015 08:40
(ShareCast News) - UK stocks dropped after a worse-than-anticipated report on Chinese manufacturing added to concerns about the slowdown in the world's second largest economy. The official government's purchasing mangers' index on manufacturing showed a reading of 49.8 for October, unchanged from th
Read moreHikma Pharmaceuticals trims guidance on generics business
2nd Nov 2015 07:40
(ShareCast News) - Hikma Pharmaceuticals said most of its businesses have performed well in the year to date, although the generics division is currently below its expectations due to slower-than-expected growth in colchicine sales. The company said it continues to see good demand for legacy product
Read moreLondon midday: Stocks higher after China exports fall less than forecast
8th Sep 2015 11:54
(ShareCast News) - London stocks were sitting higher after a better-than-expected report on Chinese exports lifted sentiment. China's exports dropped 5.5% in August from a year earlier in dollar terms after a 8.3% drop in July, according to the General Administration of Customs, better than the 6.6%
Read moreHikma Pharmaceuticals inks deal to buy Egypt-based EIMC United
8th Sep 2015 07:49
(ShareCast News) - Hikma Pharmaceuticals has agreed to acquire almost the entire share capital of Egypt-based EIMC United Pharmaceuticals (EUP) from a consortium of shareholders for an undisclosed sum. EUP is a pharmaceutical manufacturing company specialising in oncology products and Hikma said the
Read moreLondon close: Equities drop after worse-than-forecast non-farms
4th Sep 2015 16:11
(ShareCast News) - Equities in the UK market ended lower on Friday after the US non-farm payrolls report missed forecasts. American employers added 173,000 jobs in August following an upwardly revised 245,000 in July, data released on Friday by the Labor Department showed. The figure was the smalle
Read moreBroker tips: Hikma Pharmaceuticals, BP, GKN
4th Sep 2015 14:00
(ShareCast News) - Goldman Sachs upgraded Hikma Pharmaceuticals to 'buy' from 'neutral', added the stock to its regional stock 'focus list' and lifted its price target to 2,840p from 2,210p. "We see the acquisition of Roxane Labs as the realisation of large transformational M&A that we had expected
Read moreFTSE 100 movers: Hikma nudges up on Goldman upgrade, miners slide
4th Sep 2015 12:06
(ShareCast News) - London's top-flight index was down 2.2% to 6,059.90 at 1515 BST, extending earlier losses following a weaker-than-expected US nonfarm payrolls report. Hikma Pharmaceuticals nudged a little higher after Goldman Sachs upgraded the stock to 'buy' from 'neutral' and lifted its price t
Read moreGoldman Sachs upgrades Hikma on Roxane Labs acquisition
4th Sep 2015 11:52
(ShareCast News) - Goldman Sachs upgraded Hikma Pharmaceuticals to 'buy' from 'neutral', added the stock to its regional stock 'focus list' and lifted its price target to 2,840p from 2,210p. "We see the acquisition of Roxane Labs as the realisation of large transformational M&A that we had expected
Read moreFTSE 100 movers: Ashtead jumps on strong interims; Glencore, BP in the red
2nd Sep 2015 13:16
(ShareCast News) - London's FTSE 100 was up 1% to 6,116 at 1423 BST in a choppy session as stocks rebounded from weakness on Tuesday. Industrial equipment rental firm Ashtead was the standout gainer after it posted better-than-expected first quarter pre-tax profits of £155m, up 23%, driven by solid
Read moreHikma Pharmaceuticals shoots higher as Barclays hails Roxane deal
2nd Sep 2015 11:57
(ShareCast News) - Hikma Pharmaceuticals got a shot in the arm on Wednesday as Barclays lifted its price target on the stock to 2,760p from 2,050p. The bank said Hikma has transformed its US exposure and long-term visibility through the $2.65bn acquisition of US specialty generics company Roxane. "
Read moreFTSE 100 movers: Glencore drags blue chips lower
19th Aug 2015 14:38
(ShareCast News) - Following the downbeat overnight sessions elsewhere, the FTSE 100 shot lower in early trade and by the afternoon had failed to crawl higher. By 1545, the blue chip index was down 1.35% at 6,438.07 points, with only a dozen companies' shares in positive territory. Leading the fall
Read more